Guided Therapeutics

Guided Therapeutics EBIT per Employee

The EBIT per Employee of Guided Therapeutics (GTHP) as of Oct 27, 2026 is -395,333.33 USD. In the previous year, EBIT per Employee was -351,333.33 USD — a change of 12.52% (lower).

EBIT per Employee

-395,333.33USD

YoY

12.52%

Last updated:

EBIT per Employee of Guided Therapeutics is 2025 -395,333.33 USD. EBIT per Employee of Guided Therapeutics was 2024 -351,333.33 USD. It decreases by 12.52% lower compared to the previous year.

The Guided Therapeutics EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-258,000.00 USD
Jan 1, 2019
-156,166.67 USD
Jan 1, 2020
-175,333.33 USD
Jan 1, 2021
-393,666.67 USD
Jan 1, 2022
-555,500.00 USD
Jan 1, 2023
-576,166.67 USD
Jan 1, 2024
-351,333.33 USD
Jan 1, 2025
-395,333.33 USD
The Guided Therapeutics EBIT per Employee history
YEAREBIT per EmployeeYoY
-395,333.33USD+12.52%
-351,333.33USD-39.02%
-576,166.67USD+3.72%
-555,500.00USD+41.11%
-393,666.67USD+124.52%
-175,333.33USD+12.27%
-156,166.67USD-39.47%
-258,000.00USD-50.40%
-520,166.67USD-18.30%
-636,666.67USD-38.68%
-1.04 MUSD-28.06%
-1.44 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics, Inc. develops medical devices focused on cancer detection using biophotonics. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device for cervical cancer screening and triage. LuViva analyzes reflected and fluorescent light after scanning the cervix with light, offering an alternative to conventional tests. The firm targets healthcare providers and clinics seeking point-of-care solutions for cervical cancer detection. LuViva is designed for two main applications: as a screening tool for early detection of cervical cancer and precancers, and as a triage method to reduce unnecessary follow-up procedures. The company focuses on selling and marketing this device to medical facilities, emphasizing its painless, non-invasive nature and point-of-care functionality. Guided Therapeutics conducts limited clinical studies using its biophotonic technology to support the device's efficacy. The business model centers on the commercialization of LuViva, with the company developing prototypes and conducting clinical studies to validate its biophotonic detection method. Guided Therapeutics aims to position LuViva as a standard in cervical cancer screening, targeting healthcare providers who prioritize non-invasive, efficient diagnostic tools. The firm's revenue comes from the sale of LuViva devices and related services to medical institutions. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

EBIT per Employee of Guided Therapeutics is -395,333.33 USD in 2025.

EBIT per Employee of Guided Therapeutics changed from -351,333.33 USD to -395,333.33 USD, representing a 12.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Guided Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Guided Therapeutics

All Key Metrics — Guided Therapeutics